24.5
View the full transcript and gain access to JoVE Core videos
Q1: What is the difference between affinity and avidity in antibody-antigen interactions?
Affinity measures the strength of interaction between a single antibody and a single epitope on an antigen. Avidity refers to the cumulative binding strength when a multivalent antibody binds multiple epitopes simultaneously. High avidity antibodies typically have low affinity for individual epitopes but achieve strong overall binding through multiple contact points.
Q2: How does antibody affinity change during repeated exposure to the same antigen?
During initial pathogen exposure, antibodies produced have low affinity for the antigen. However, repeated encounters trigger an adaptive selection process that produces antibodies with progressively higher affinity. This affinity maturation results in stronger and faster immune responses upon subsequent exposures to the same pathogen.
Q3: Why do multivalent antibodies like IgM have high avidity but low affinity?
IgM antibodies possess multiple binding sites recognizing the same epitope, creating high cumulative binding strength or avidity. However, individual binding interactions have low affinity. This design allows IgM to quickly recognize new antigens without requiring elaborate selection processes, making it ideal for initial immune responses.
Q4: What role does the epitope play in antibody-antigen binding?
An epitope is the precise binding site on an antigen where an antibody makes contact. The strength of interaction between an antibody and a specific epitope defines that antibody's affinity. Different epitopes on the same antigen can be recognized by different antibodies, allowing varied immune responses.
Q5: How does varying antibody affinity optimize the immune response to pathogens?
Low-affinity antibodies from initial exposures provide basic pathogen recognition and tagging for destruction. As the immune system encounters the same pathogen repeatedly, higher-affinity antibodies are produced, enabling stronger binding, more efficient pathogen neutralization, and faster immune responses during subsequent infections.
Q6: What is the functional advantage of IgM antibodies in early immune responses?
IgM antibodies are produced quickly during early immune responses because they do not undergo elaborate affinity selection processes. Their high avidity compensates for low individual binding affinity, allowing them to recognize new antigens effectively. IgM also triggers B cells to produce other antibody classes with higher affinity against newly identified antigens.
Q7: How do antibodies prevent pathogen infection and facilitate destruction?
Antibodies bind to antigens on pathogen surfaces through antibody-antigen interactions, preventing the pathogen from infecting other cells. Simultaneously, these bound antibodies tag pathogens for destruction by immune system components. The strength of these interactions, determined by affinity and avidity, directly influences the effectiveness of the immune response.